VELTASSA® (patiromer) for oral suspension

Indication and Usage

VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Important Safety Information

Contraindications: VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components. Please see additional Important Safety Information Important Safety Information below and full Prescribing Information.

Are your patients struggling to maintain normokalemia?

Explore patient profiles to see if VELTASSA may be right for your patients.

  • MILD
    HYPERKALEMIA
  • CHRONIC
    HYPERKALEMIA
  • EMERGENT
    HYPERKALEMIA

Mild
Hyperkalemia

 

PATIENT CASE AND IMAGE ARE PORTRAYALS

Do you have a patient with mild hyperkalemia who is taking a RAAS inhibitor?

  • Worsening heart failure symptoms
  • Recently up-titrated Lisinopril
  • Incrementally increasing serum K+

Initiate VELTASSA at 8.4 g/day* to achieve and maintain normokalemia for the long term.

Relevant Medication
  • Furosemide 40 mg BID
  • Carvedilol IR 25 mg BID
  • Spironolactone 25 mg QD
  • Lisinopril 40 mg QD
  • Simvastatin 40 mg QD
  • Warfarin (last INR 2.5)
  • Aspirin 81 mg QD
Medical History
  • Heart failure (NYHA Class II, evolving to Class III)
  • CAD with prior MI and CABG
  • Atrial fibrillation
  • Hypertension
  • Deteriorating renal function—creatinine 2.1 mg/dL (0.3 mg/dL increase in past 2 months)

BID=twice daily; CABG=coronary artery bypass grafting; CAD=coronary artery disease;
INR=international normalized ratio; MI=myocardial infarction; NYHA=New York Heart
Association; QD=once daily; RAAS=renin-angiotensin-aldosterone system.

*Recommended starting dose for VELTASSA is 8.4 g/day.

 

What were the results in a VELTASSA clinical trial that included patients treated with RAAS inhibitors?

FIND OUT

Chronic
Hyperkalemia

 

PATIENT CASE AND IMAGE ARE PORTRAYALS

Do you have a CKD patient with chronic hyperkalemia?

Progressively declining kidney function has led to increased proteinuria and a steady state of chronically elevated K+ levels.1

Initiate VELTASSA at 8.4 g/day* to achieve and maintain normokalemia for the long term.

Relevant Medication
  • Losartan 50 mg QD
  • Furosemide 40 mg BID
  • Aspirin 81 mg QD
  • Sitagliptin 100 mg QD
  • Sodium bicarbonate PRN
Medical History
  • Stage 3b CKD
  • Creatinine 1.5 mg/dL
  • Hypertension
  • Diabetic nephropathy
  • Coronary artery disease

BID=twice daily; CKD=chronic kidney disease; PRN=as needed; QD=once daily;
RAAS=renin-angiotensin-aldosterone system.

*Recommended starting dose for VELTASSA is 8.4 g/day.

 

How can VELTASSA help your patients sustain normokalemia for the long term?

FIND OUT

Emergent
Hyperkalemia

 

PATIENT CASE AND IMAGE ARE PORTRAYALS

Do you have a patient who has had an acute hyperkalemic event?

  • Presenting with fatigue and malaise in ER
  • Serum K+ dangerously elevated and ECG changes consistent with hyperkalemia

After emergent treatment (calcium gluconate and insulin infusion), serum K+ was reduced to 5.7 mEq/L

Initiate VELTASSA at 8.4 g/day* to achieve normokalemia and continue to monitor serum K+ levels. VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Relevant Medication
  • Hydralazine 37.5 mg/ISDN 20 mg—1 tab TID
  • Furosemide 40 mg QD
  • Carvedilol ER 10 mg QD
  • Erythropoietin 50 IU 3×/week
  • Basal insulin 20 IU
Medical History
  • CKD stage 4
  • Creatinine 3.2 mg/dL
  • Heart failure (NYHA Class II)
  • Type 2 diabetes mellitus
  • Hypertension

CKD=chronic kidney disease; ECG=electrocardiogram; ER=emergency room;
ISDN=isosorbide dinitrate; IU=international units; NYHA=New York Heart Association;
QD=once daily; RAAS=renin-angiotensin-aldosterone system; TID=3 times a day.

*Recommended starting dose for VELTASSA is 8.4 g/day.

 

How does VELTASSA treat hyperkalemia in the inpatient setting?

FIND OUT

Important Safety Information, including Boxed WARNING

Indication and Usage

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life‑threatening hyperkalemia because of its delayed onset of action.


Important Safety Information

Contraindications: VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

Adverse Reactions: The most common adverse reactions (incidence ≥2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please see full Prescribing Information Prescribing Information The VELTASSA Prescribing Information has been updated to remove the Boxed WARNING for binding to other oral medications. Administer VELTASSA at least 3 hours before or 3 hours after other oral medications. Please see Section 12.3 for detailed drug interactions.
Continue
.

Reference: 1. Gennari FJ, Segal AS. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int. 2002;62:1-9.